Business Wire

Hanshow Makes US Market Debut at 2022 NRF Big Show

Share

Global digital retail solutions provider Hanshow is making its US market debut this week at the annual NRF Big Show in New York where it’s showcasing a series of new products, announcements, and partnerships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220114005005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2022 NRF venue, the Javits Center in New York (Photo: Business Wire)

Hanshow was founded ten years ago with an initial focus on just electronic shelf labels (ESL). After often triple digit annual growth, expansion across Europe, Asia Pacific and 50 countries around the world, the company is now bringing its impressive suite of digital retail solutions to the world’s largest retail market.

Now after a decade of tested results with some of the world’s leading retailers including Auchan, Ahold Delhaize, Yamada Denki and many more, Hanshow believes it has the solutions US retailers need to evolve and thrive in this period of uncertainty for the retail. The company arrives in the US at a time when its retail industry is facing dramatic changes from surging ecommerce, labor shortages, fluctuating prices, and supply chain disruptions.

“Hanshow’s digital solutions address all of these challenges by adding automation, remote management, and efficiency upgrades for omnichannel retail,” according to Li Liangyan, Hanshow Senior Vice President.

In 2021 Hanshow opened its first US office in New York where it will base its expansion of digital solutions for US retailers. This is also the company’s first major showing at the annual NRF Big Show. At this year’s NRF, Hanshow is demonstrating its technology for solving this range of retailer pain points.

Its Nebular ESL replaces paper price tags and has a battery life of up to 15 years, and includes a location lighting function that reduces in-store picking times for delivery by up to 68%. Hanshow’s Lumina LCD screens act as a dynamic content display designed for fresh food sections that has led to marked sales increases and reduced food waste. When managed through Hanshow’s SaaS, based on Microsoft Azure, these ESL and digital screens also allow for entire store networks to update their prices in minutes from centralized locations, a crucial advantage as many stores face labor shortages.

Hanshow is also showcasing its AI solution that uses fixed cameras and mobile robots for on-shelf status monitoring and fresh foods management. While its self-service kiosk and digital screen equipped smart trolley allow for easy scan and go payments without a register. All of these products are adaptable across a range of retail from supermarkets to electronics and apparel, and several are already in the proof-of-concept phase with several retailers in the US.

These solutions also function within a technology ecosystem, as Hanshow is partnering with some of the world’s leading companies to bring added benefits for clients including being a partner in the recently announced Microsoft Cloud for Retail, while also having integrated solutions with Aruba, PwC, Lenovo, and Sony.

“We have the some of the best partnerships, biggest clients, best technology, and best track record in the industry,” notes Li Liangyan, “we are excited to bring this all together for the vital US retail market.”

Hanshow’s solutions are on display at Level 1 booth 661 this week at the NRF Big Show, Javits Center, New York.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media inquires:
Steve Blake steve.blake@hanshow.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye